Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
0.3474
+0.0177 (5.37%)
At close: Apr 8, 2026, 4:00 PM EDT
0.3381
-0.0093 (-2.68%)
After-hours: Apr 8, 2026, 5:49 PM EDT
Gossamer Bio Employees
As of December 31, 2025, Gossamer Bio had 162 total employees, including 161 full-time and 1 part-time employees. The number of employees increased by 17 or 11.72% compared to the previous year.
Employees
162
Change (1Y)
17
Growth (1Y)
11.72%
Revenue / Employee
$299,204
Profits / Employee
-$1,051,667
Market Cap
81.53M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 162 | 17 | 11.72% | 161 | 1 |
| Dec 31, 2024 | 145 | 10 | 7.41% | 144 | 1 |
| Dec 31, 2023 | 135 | -43 | -24.16% | 135 | 0 |
| Dec 31, 2022 | 178 | -7 | -3.78% | 178 | 0 |
| Dec 31, 2021 | 185 | -11 | -5.61% | 185 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Rani Therapeutics Holdings | 106 |
| Fortress Biotech | 101 |
| Pelthos Therapeutics | 92 |
| PolyPid | 75 |
| aTyr Pharma | 60 |
| Pliant Therapeutics | 49 |
| Cognition Therapeutics | 28 |
| Gain Therapeutics | 25 |
GOSS News
- 22 days ago - Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update - Business Wire
- 4 weeks ago - Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1 - Benzinga
- 5 weeks ago - GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 6 weeks ago - BREAKING: Gossamer Bio Investors Should Contact Block & Leviton to Potentially Recover Losses After Shares Fall Over 75% - GlobeNewsWire
- 6 weeks ago - Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 6 weeks ago - Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks - Benzinga
- 6 weeks ago - Gossamer Bio's experimental lung condition drug fails in late-stage trial - Reuters
- 6 weeks ago - Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension - Business Wire